Geron Corporation is a late-stage clinical biopharmaceutical company developing investigational first-in-class telomerase inhibitor, imetelstat, to treat hematologic malignancies. The Company is engaged in the development of therapeutic products for oncology. Its lead indication for imetelstat is in Low or Intermediate-1 risk myelodysplastic syndromes.
It is developing imetelstat for the treatment of several myeloid hematologic malignancies, including a Phase 3 clinical trial, named IMpactMF, in relapsed/refractory myelofibrosis (MF) with overall survival as the primary endpoint, that is enrolling patients. It is also conducting a Phase 1 combination therapy clinical trial, named IMproveMF, in first-line Intermediate-1, Intermediate-2 or High-Risk myelofibrosis, or frontline MF, that is enrolling patients and imetelstat is being studied in an investigator-led Phase 2 clinical trial, named IMpress, in Intermediate-2 or High-Risk myelodysplastic syndromes and acute myeloid leukemia..
| Price and Volume | |
|---|---|
| Volume | |
| Ten Day Average Volume | 6.7M | 
| Three Month Average Volume | 249.5M | 
| High Low | |
| Fifty-Two Week High | 5.34 USD | 
| Fifty-Two Week Low | 1.64 USD | 
| Fifty-Two Week High Date | 12 Jun 2024 | 
| Fifty-Two Week Low Date | 13 Mar 2024 | 
| Price and Volume | |
| Current Price | 4.75 USD | 
| Beta | 1 | 
| Relative Price Change | |
| Four Week Relative Price Change | -1.62% | 
| Thirteen Week Relative Price Change | 25.02% | 
| Twenty-Six Week Relative Price Change | 91.15% | 
| Fifty-Two Week Relative Price Change | 56.00% | 
| Year-to-Date Relative Price Change | 90.10% | 
| Price Change | |
| One Day Price Change | 4.17% | 
| Thirteen Week Price Change | 33.80% | 
| Twenty-Six Week Price Change | 110.18% | 
| Five Day Price Change | 4.63% | 
| Fifty-Two Week Price Change | 95.47% | 
| Year-to-Date Price Change | 125.12% | 
| Month-to-Date Price Change | 0.21% | 
| Per Share Data | |
|---|---|
| Book Value | |
| Book Value Per Share (Last Fiscal Year) | 0.45503 USD | 
| Book Value Per Share (Most Recent Quarter) | 0.51027 USD | 
| Tangible Book Value Per Share (Last Fiscal Year) | 0.45503 USD | 
| Tangible Book Value Per Share (Most Recent Quarter) | 0.51027 USD | 
| EBITD | |
| EBITD Per Share (Trailing Twelve Months) | -0.37296 USD | 
| Revenue | |
| Revenue Per Share (Last Fiscal Year) | 0.00042 USD | 
| Revenue Per Share (Trailing Twelve Months) | 0.00226 USD | 
| Dividend | |
| Dividend Per Share (Last Fiscal Year) | -99999.99 USD | 
| Dividend Per Share (Trailing Twelve Months) | 0 USD | 
| Dividend Per Share (5 Year) | -99999.99 USD | 
| Earnings Per Share | |
| Excluding Extraordinary Items (Last Fiscal Year) | -0.32266 USD | 
| Excluding Extraordinary Items (Trailing Twelve Months) | -0.35946 USD | 
| Normalized (Last Fiscal Year) | -0.32266 USD | 
| Basic Excluding Extraordinary Items (Last Fiscal Year) | -0.32266 USD | 
| Basic Excluding Extraordinary Items (Trailing Twelve Months) | -0.35946 USD | 
| Including Extraordinary Items (Last Fiscal Year) | -0.32266 USD | 
| Including Extraordinary Items (Trailing Twelve Months) | -0.35946 USD | 
| Cash | |
| Cash Per Share (Last Fiscal Year) | 0.61239 USD | 
| Cash Per Share (Most Recent Quarter) | 0.6035 USD | 
| Cash Flow Per Share (Last Fiscal Year) | -0.32189 USD | 
| Cash Flow Per Share (Trailing Twelve Months) | -0.3601 USD | 
| Free Cash Flow Per Share (Trailing Twelve Months) | -0.34305 USD | 
| Margins | |
|---|---|
| Cash Flow Revenue | |
| Cash Flow Revenue (5 Year) | -17,130 | 
| Cash Flow Revenue (Trailing Twelve Months) | -15,192 | 
| Pretax Margin | |
| Pretax Margin (Trailing Twelve Months) | -15,990.60% | 
| Pretax Margin (Last Fiscal Year) | -77,690.72% | 
| Pretax Margin (5 Year) | -19,949.13% | 
| Gross Margin | |
| Gross Margin (Last Fiscal Year) | -99,999.99% | 
| Gross Margin (Trailing Twelve Months) | 63.00% | 
| Gross Margin (5 Year) | -99,999.99% | 
| Operating Margin | |
| Operating Margin (Last Fiscal Year) | -81,832.91% | 
| Operating Margin (Trailing Twelve Months) | -16,559.94% | 
| Operating Margin (5 Year) | -20,275.98% | 
| Net Profit Margin | |
| Net Profit Margin (Last Fiscal Year) | -77,690.72% | 
| Net Profit Margin (Trailing Twelve Months) | -15,990.60% | 
| Net Profit Margin (5 Year) | -19,949.13% | 
| Growth | |
|---|---|
| Book Value | |
| Book Value Per Share (5 Year) | -13.75% | 
| Tangible Book Value (5 Year) | 6.89% | 
| Free Operating Cash Flow | |
| Free Operating Cash Flow (5 Year) | -99,999.99% | 
| Revenue | |
| Revenue Change MRQ vs 1 Year Ago | 2,941.38% | 
| Revenue Growth (3 Year) | -25.97% | 
| Revenue Change (Trailing Twelve Months) | 205.11% | 
| Revenue Per Share Growth | -41.46% | 
| Revenue Growth (5 Year) | -2.15% | 
| Capital Spending Debt | |
| Capital Spending (5 Year) | 120.29% | 
| Total Debt (5 Year) | -99,999.99% | 
| Dividends | |
| Dividend Growth (3 Year) | -99,999.99% | 
| Earnings Per Share | |
| EPS Change MRQ vs 1 Year Ago | -14.56% | 
| EPS Change (Trailing Twelve Months) | 3.66% | 
| EPS Growth (3 Year) | -99,999.99% | 
| EPS Growth (5 Year) | -99,999.99% | 
| EBITDA | |
| EBITDA (5 Year) | -99,999.99% | 
| EBITDA (5 Year Interim) | -99,999.99% | 
| Net Profit Margin | |
| Net Profit Margin Growth (5 Year) | -99,999.99% | 
| Valuation | |
|---|---|
| Total Price to Book | |
| Price to Tangible Book (Last Fiscal Year) | 12 | 
| Price to Tangible Book (Most Recent Quarter) | 9 | 
| Price to Free Cash Flow | |
| Price to Free Cash Per Share (Last Fiscal Year) | -100,000 | 
| Price to Free Cash Per Share (Trailing Twelve Months) | -100,000 | 
| Net Debt | |
| Net Debt (Most Recent Quarter) | -279,298,000 | 
| Net Debt (Last Fiscal Year) | -251,755,000 | 
| Price to Sales | |
| Price to Sales (Last Fiscal Year) | 12.1K | 
| Price to Sales (Trailing Twelve Months) | 2.1K | 
| Price to Earnings | |
| PE Excluding Extraordinary Items (Last Fiscal Year) | -100,000 | 
| PE Normalized (Last Fiscal Year) | -100,000 | 
| PE Basic Excluding Extraordinary Items (Trailing Twelve Months) | -100,000 | 
| PE Excluding Extraordinary Items High (Trailing Twelve Months) | -100,000 | 
| PE Excluding Extraordinary Items Low (Trailing Twelve Months) | -100,000 | 
| PE Including Extraordinary Items (Trailing Twelve Months) | -100,000 | 
| Dividends | |
| Dividend Yield (5 Year) | -99,999.99% | 
| Dividend Yield | -99,999.99% | 
| Current Dividend Yield | 0.00% | 
| Price to Book | |
| Price to Book (Last Fiscal Year) | 10 | 
| Price to Book (Most Recent Quarter) | 9 | 
| Financial Strength | |
|---|---|
| Debt to Equity | |
| Long Term Debt to Equity (Last Fiscal Year) | 14 | 
| Long Term Debt to Equity (Most Recent Quarter) | 12 | 
| Payout Ratio | |
| Payout Ratio (Last Fiscal Year) | -99,999.99% | 
| Payout Ratio (Trailing Twelve Months) | -99,999.99% | 
| Quick Ratio | |
| Quick Ratio (Last Fiscal Year) | -100,000 | 
| Quick Ratio (Most Recent Quarter) | 4 | 
| Enterprise Value | |
| Current Enterprise Value to Free Cash Flow (Last Fiscal Year) | -100,000 | 
| Current Enterprise Value to Free Cash Flow (Trailing Twelve Months) | -100,000 | 
| Current Ratio | |
| Current Ratio (Last Fiscal Year) | 3 | 
| Current Ratio (Most Recent Quarter) | 4 | 
| Free Cash Flow | |
| Free Cash Flow (Last Fiscal Year) | -168,573,000 | 
| Free Cash Flow (Trailing Twelve Months) | -208,585,000 | 
| Net Interest Coverage | |
| Net Interest Coverage (Last Fiscal Year) | -100,000 | 
| Net Interest Coverage (Trailing Twelve Months) | -100,000 | 
| Total Debt to Equity | |
| Total Debt to Equity (Last Fiscal Year) | 33 | 
| Total Debt to Equity (Most Recent Quarter) | 27 | 
| Management Effectiveness | |
|---|---|
| Return on Assets | |
| Return on Assets (Last Fiscal Year) | -62.99% | 
| Return on Assets (Trailing Twelve Months) | -50.78% | 
| Return on Assets (5 Year) | -51.32% | 
| Return on Equity | |
| Return on Equity (Last Fiscal Year) | -112.29% | 
| Return on Equity (Trailing Twelve Months) | -72.56% | 
| Return on Equity (5 Year) | -76.61% | 
| Return on Investment | |
| Return on Investment (Last Fiscal Year) | -92.09% | 
| Return on Investment (Trailing Twelve Months) | -63.77% | 
| Return on Investment (5 Year) | -64.90% |